Table 3. The characteristics of patients in ER+/ HER2- metastatic cancer cohort by BIM deletion polymorphism.
| Characteristics | No. | No. (%) | ||
|---|---|---|---|---|
| All (n = 189) | BIM wild (n = 153) | BIM deleted (n = 36) | P value | |
| Age at initial diagnosis | 0.023* | |||
| ≤35 years | 15 | 9 (60) | 6 (40) | |
| 36–50 years | 80 | 62 (78) | 18 (23) | |
| >50 years | 94 | 82 (87) | 12 (13) | |
| Histology | 0.374 | |||
| Ductal carcinoma | 162 | 133 (82) | 29 (18) | |
| Others | 19 | 14 (74) | 5 (26) | |
| Unknown | 8 | 6 | 2 | |
| Grade | 0.583 | |||
| I | 27 | 22 (81) | 5 (19) | |
| II | 75 | 62 (83) | 13 (17) | |
| III | 29 | 22 (76) | 7 (24) | |
| Unknown | 58 | 47 | 11 | |
| PR Status | 0.139 | |||
| Negative | 61 | 53 (87) | 8 (13) | |
| Positive | 126 | 98 (78) | 28 (22) | |
| Unknown | 2 | 2 | 0 | |
DFI, disease-free interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
*two tailed Fisher’s exact test.